Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Fig. 2

Parameter effect on clearance: a Estimated nivolumab clearance (L/day) as a function of a baseline serum albumin (g/L) and b body surface area (BSA; m2). Single measurements are represented by open circles. The red line predicts clearance according to the final PPK model (Mf). The horizontal dotted lines marks the 20% increase of clearance, taking the mean clearance as reference (solid line). The vertical dotted line mark the threshold where nivolumab clearance is expected to be increased by > 20%

Back to article page